Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company will be held on 30th May 2023 inter-alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023.Further in continuation of our earlier letter dated 9th May 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for dealing in the securities of the Company shall remain closed upto 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended on 31st March 2023.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
